Correction: Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway

Baoshi Yuan, Kexin Shi, Juanmin Zha, Yujia Cai, Yue Gu, Kai Huang, Wenchang Yue, Qiaocheng Zhai, Ning Ding, Wenyan Ren, Wei He, Ying Xu, Tao WangCell 2025 · DOI · OpenAlex

Introduction

This document serves as a formal correction to the research article titled "Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway," which was originally published in the journal Cell Death & Disease in January 2023. The primary purpose of this update is to rectify an administrative error in the funding acknowledgments to ensure accurate institutional and financial reporting.

CDDpress Logo

Context of the Original Research

The original study investigated the therapeutic potential of nuclear receptor modulators in treating osteosarcoma, a malignant bone cancer. By focusing on the mTOR (mammalian target of rapamycin) signaling pathway—a key regulator of cell growth and metabolism—the researchers explored mechanisms to inhibit tumor progression. The study utilized U2OS osteosarcoma cell lines, which were provided by Dr. Eric Zhang, to demonstrate how these modulators could effectively curb cell proliferation and tumor growth.

Details of the Correction

Following the publication of the article, it was discovered that one of the grant identifiers associated with the funding of the research was listed incorrectly. Accurate funding attribution is a cornerstone of scientific transparency, allowing funding bodies to track the impact of their investments and ensuring researchers comply with grant requirements.

Check for updates

The correction specifically addresses the identifier for the Livelihood and Technology Program of Suzhou City. In the original version of the paper, the grant number was cited as "N324560122." This has now been officially corrected to the proper identifier: SKY2022106.

Updated Acknowledgment Section

The acknowledgment section of the article has been updated to reflect the correct financial support. The revised text is as follows:

“We are very grateful to Dr. Eric Zhang for providing the U2OS cells. This work was supported by the grants from National Natural Science Foundation of China (31601022), National Key R&D Program of China (2018YFA0801104) and The Livelihood and Technology Program of Suzhou City (SKY2022106).”

Significance of the Update

While this administrative change does not affect the scientific results, data interpretation, or the conclusions of the osteosarcoma research, it is essential for maintaining the integrity of the academic record. Other primary funding sources, including the National Natural Science Foundation of China (31601022) and the National Key R&D Program of China (2018YFA0801104), remain unchanged and were correctly attributed in the initial publication.

Journals and authors share a responsibility to ensure that metadata—such as funding sources—remains precise, even years after the initial publication. This correction ensures that the Livelihood and Technology Program of Suzhou City receives proper credit for its role in supporting this oncological research.

Summary updated

BibTeX
@inproceedings{yuan2025correction,
  author = {Baoshi Yuan and Kexin Shi and Juanmin Zha and Yujia Cai and Yue Gu and Kai Huang and Wenchang Yue and Qiaocheng Zhai and Ning Ding and Wenyan Ren and Wei He and Ying Xu and Tao Wang},
  title = {{Correction: Nuclear receptor modulators inhibit osteosarcoma cell proliferation and tumour growth by regulating the mTOR signaling pathway}},
  booktitle = {Cell},
  year = {2025},
  doi = {10.1038/s41419-025-07409-2},
}
Figure